From: Prognosis prediction in esophageal signet-ring-cell carcinoma: a competing risk analysis
Characteristics | Training Cohort (N = 282) | Validation Cohort (N = 282) | ||||
---|---|---|---|---|---|---|
SHR | 95% CI | P value | SHR | 95% CI | P value | |
Age | ||||||
 ≤ 65 | Reference |  |  | Reference |  |  |
 > 65 | 0.93 | 0.676–1.28 | 0.66 | 1.139 | 0.823–1.576 | 0.43 |
Sex | ||||||
 Female | Reference |  |  | Reference |  |  |
 Male | 2.309 | 1.259–4.236 | 0.007 | 1.641 | 0.893–3.017 | 0.11 |
Race | ||||||
 Others | Reference |  |  | Reference |  |  |
 White | 0.712 | 0.436–1.165 | 0.18 | 1.164 | 0.683–1.985 | 0.58 |
Marital status | ||||||
 Widowed/others | Reference |  |  | Reference |  |  |
 Divorced/Separated | 1.033 | 0.523–2.042 | 0.92 | 0.885 | 0.448–1.748 | 0.73 |
 Married | 0.878 | 0.539–1.428 | 0.6 | 0.767 | 0.469–1.255 | 0.29 |
 Single/Unmarried | 0.963 | 0.525–1.766 | 0.9 | 0.947 | 0.539–1.662 | 0.85 |
History of Malignancy | ||||||
 Previously | Reference |  |  | Reference |  |  |
 Newly | 1.897 | 0.652–5.52 | 0.24 | 0.715 | 0.284–1.802 | 0.48 |
Primary Site | ||||||
 Others | Reference |  |  | Reference |  |  |
 15-32 cm | 1.244 | 0.625–2.476 | 0.53 | 1.55 | 0.527–4.588 | 0.43 |
 33-40 cm | 0.647 | 0.376–1.113 | 0.12 | 2.612 | 1.182–5.772 | 0.018 |
Grade | ||||||
 I-II | Reference |  |  | Reference |  |  |
 III-IV | 1.143 | 0.485–2.696 | 0.76 | 1.314 | 0.716–2.412 | 0.38 |
 Others | 1.252 | 0.5–3.134 | 0.63 | 1.184 | 0.592–2.37 | 0.63 |
AJCC Stage | ||||||
 I | Reference |  |  | Reference |  |  |
 II | 1.564 | 0.678–3.609 | 0.29 | 2.069 | 0.977–4.38 | 0.058 |
 III | 1.899 | 0.769–4.686 | 0.16 | 4.336 | 1.883–9.987 | < 0.001 |
 IV | 2.358 | 0.99–5.614 | 0.053 | 3.173 | 1.435–7.017 | 0.004 |
Tumor Size | ||||||
 T1 | Reference |  |  | Reference |  |  |
 T2 | 1.117 | 0.599–2.085 | 0.73 | 0.676 | 0.337–1.355 | 0.27 |
 T3 | 0.799 | 0.489–1.306 | 0.37 | 0.388 | 0.218–0.691 | 0.001 |
 T4 | 0.819 | 0.439–1.529 | 0.53 | 0.441 | 0.235–0.827 | 0.011 |
 TX | 0.608 | 0.319–1.157 | 0.13 | 0.65 | 0.32–1.32 | 0.23 |
Node Status | ||||||
 N0 | Reference |  |  | Reference |  |  |
 N1 | 1.103 | 0.685–1.775 | 0.69 | 0.71 | 0.444–1.136 | 0.15 |
 N2 | 0.952 | 0.51–1.779 | 0.88 | 0.548 | 0.285–1.054 | 0.072 |
 N3/NX | 1.128 | 0.54–2.354 | 0.75 | 0.588 | 0.251–1.376 | 0.22 |
Regional Nodes Examined | ||||||
 0 | Reference |  |  | Reference |  |  |
 0–10 | 1.286 | 0.653–2.533 | 0.47 | 0.962 | 0.297–3.112 | 0.95 |
 11–60 | 1.007 | 0.482–2.106 | 0.98 | 0.408 | 0.128–1.304 | 0.13 |
Positive Lymph Nodes | ||||||
 0 | Reference |  |  | Reference |  |  |
 0–2 | 1.006 | 0.523–1.936 | 0.99 | 1.92 | 0.809–4.588 | 0.14 |
 3–35 | 1.537 | 0.706–3.346 | 0.28 | 2.949 | 0.94–9.253 | 0.064 |
Bone Metastases | ||||||
 NO/Unknown | Reference |  |  | Reference |  |  |
 YES | 1.105 | 0.614–1.988 | 0.74 | 2.125 | 1.215–3.717 | 0.008 |
Liver Metastases | ||||||
 NO/Unknown | Reference |  |  | Reference |  |  |
 YES | 1.573 | 0.848–2.919 | 0.15 | 2.238 | 1.301–3.85 | 0.004 |
Lung Metastases | ||||||
 NO/Unknown | Reference |  |  | Reference |  |  |
 YES | 2.364 | 1.187–4.709 | 0.014 | 1.552 | 0.743–3.241 | 0.24 |
Surgery | ||||||
 NO | Reference |  |  | Reference |  |  |
 YES | 0.497 | 0.271–0.91 | 0.024 | 0.331 | 0.116–0.948 | 0.039 |
Radiotherapy | ||||||
 NO | Reference |  |  | Reference |  |  |
 YES | 1.098 | 0.616–1.956 | 0.75 | 1.991 | 1.014–3.906 | 0.045 |
Chemotherapy | ||||||
 NO | Reference |  |  | Reference |  |  |
 YES | 0.82 | 0.498–1.351 | 0.44 | 0.757 | 0.491–1.168 | 0.21 |